
Johnson & Johnson's Q1 Results, FY Guidance Highlight The 'Power Of The Pharma Portfolio'
Johnson & Johnson JNJ reported upbeat first-quarter results on Wednesday. Here are some key analyst takeaways. Goldman Sachs On Johnson & Johnson Analyst Asad Haider maintained a Buy rating and price target of $172. Despite Stelara sales declining …